Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
AmericaFirst Monthly Risk-On Risk-Off A ABRFX
- NAV / 1-Day Return 12.90 / +0.47 %
- Total Assets 4.5 Mil
-
Adj. Expense Ratio
- Expense Ratio 2.870%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Tactical Allocation
- Investment Style Large Growth
- Credit Quality / Interest Rate Sensitivity —
- Status Open
- TTM Yield —
- Turnover 326%
USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:10 PM GMT+0
Morningstar’s Analysis ABRFX
Will ABRFX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Cash & Cash Equivalents | 8.00 | 403,687 | Cash and Equivalents |
TG Therapeutics Inc | 6.28 | 317,052 | Healthcare |
Monte Rosa Therapeutics Inc | 6.10 | 308,191 | Healthcare |
Gritstone Bio Inc | 6.09 | 307,483 | Healthcare |
Nu Holdings Ltd Ordinary Shares Class A | 6.04 | 304,823 | Financial Services |
Eli Lilly and Co | 5.36 | 270,730 | Healthcare |
Novo Nordisk A/S ADR | 5.09 | 256,800 | Healthcare |
Micron Technology Inc | 4.55 | 229,532 | Technology |
NVIDIA Corp | 4.47 | 225,890 | Technology |
DraftKings Inc Ordinary Shares - Class A | 4.09 | 206,388 | Consumer Cyclical |